Review
doi: 10.1158/1078-0432.CCR-07-1385.
Targeted agents: the rules of combination
Affiliations
- PMID: 17875749
- DOI: 10.1158/1078-0432.CCR-07-1385
Item in Clipboard
Review
Targeted agents: the rules of combination
Clin Cancer Res.
.
Abstract
The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect.
Similar articles
-
Food and Drug Administration requirements for approval of new anticancer drugs.Cancer Treat Rep. 1985 Oct;69(10):1155-9. Cancer Treat Rep. 1985. PMID: 4042094
-
Recasting cancer trials.Nat Biotechnol. 2012 Jul 10;30(7):567. doi: 10.1038/nbt.2315. Nat Biotechnol. 2012. PMID: 22781659 No abstract available.
-
Combining targeted drugs to stop resistant tumors.Science. 2011 Mar 25;331(6024):1542-5. doi: 10.1126/science.331.6024.1542. Science. 2011. PMID: 21436437 No abstract available.
-
Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):805-17. doi: 10.1517/17425255.3.6.805. Expert Opin Drug Metab Toxicol. 2007. PMID: 18028026 Review.
-
Cancer drug approval in the United States, Europe, and Japan.Adv Cancer Res. 2007;96:371-91. doi: 10.1016/S0065-230X(06)96012-6. Adv Cancer Res. 2007. PMID: 17161686 Review. No abstract available.
Cited by
-
Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.J Control Release. 2019 Oct;311-312:257-272. doi: 10.1016/j.jconrel.2019.08.038. Epub 2019 Sep 5. J Control Release. 2019. PMID: 31494183 Free PMC article.
-
Editorial: Novel Combination Therapies for the Treatment of Solid Cancers.Front Oncol. 2021 Jun 18;11:708943. doi: 10.3389/fonc.2021.708943. eCollection 2021. Front Oncol. 2021. PMID: 34222030 Free PMC article. No abstract available.
-
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162. Epub 2009 Jun 30. Br J Cancer. 2009. PMID: 19568235 Free PMC article. Clinical Trial.
-
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.Molecules. 2020 Mar 25;25(7):1497. doi: 10.3390/molecules25071497. Molecules. 2020. PMID: 32218358 Free PMC article.
-
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.NPJ Precis Oncol. 2024 Feb 27;8(1):52. doi: 10.1038/s41698-024-00543-8. NPJ Precis Oncol. 2024. PMID: 38413740 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
